Sperling Prostate Center

Month: September 2015

Competition in MRI Technology

“Everyone is keeping up with the Joneses, and there are more Joneses than ever.” This statement from art critic Jerry Saltz refers to the buying habits of a public hungry for trendy art. However, it could as easily apply to MRI technology, where the strength of the magnet—measured in units called Tesla, or T—makes all keep reading

Demythologizing the Gold Standard

We live in an age of medical specialties that “compete” for patients. In women’s health, for example, treating noncancerous growths called uterine fibroid tumors has traditionally been the territory of gynecologists. Gynecologists, like urologists, were trained in surgery so they often recommend hysterectomy (surgical removal of the uterus) as the gold standard for treating severe keep reading

Statins and Prostate Cancer: An Update

Last December I posted a blog entry on the possibility that statins, a class of cholesterol-lowering drugs, can reduce the risk of developing aggressive prostate cancer (PCa). If you’re interested, I summarized the relationship between how statins control cholesterol and scientific theories about the connection with PCa; you can read it at https://sperlingprostatecenter.com/statins-prostate-cancer/. I try keep reading
WordPress Image Lightbox